Jefferies Upgrades Intellia Therapeutics (NTLA) to Buy; CRISPR Technology seen as Transformative
Tweet Send to a Friend
Jefferies upgraded Intellia Therapeutics (NASDAQ: NTLA) from Hold to Buy with a price target of $33.00, calling CRISPR technology transformative.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
